pual
2 years ago
Isracann Bioscience Facilitated Genetics Arrive in Israel - 09/28/2022 9:00:00 AM
VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) a multi-faceted Israel-based company focused on becoming a premier low cost, high quality cannabis producer/distributor is pleased to announce that previously shipped genetics have cleared Israeli customs and are being raised as mother stock.
“The Israeli market will now have access to premium Canadian high THC genetics,” notes CEO Phil Floucault. “The three strains we shipped are called: Liberty Haze, Hell Monkey, and Grape Stomper. All three strains have received a positive response from consumers in Canada and I am looking forward to being able to make them available to the Israeli market.”
The three strains sent were developed as part of United Greeneries’ “Grass Roots” genetics program, the goal of which is to produce novel high THC strains with commercially high yields. Currently being sold as premium cannabis flower in Canada, the three strains represent some of the top preforming genetics in United Greeneries’ catalogue. With the support of United Greeneries and Isracann, all three strains have been integrated into the Intelicanna facility and are being prepared as the initial Israeli mother stock.
Phil Floucault continues, “The planning and preparation by the teams in Canada and Israel made this genetics shipment happen smoothly. The growing teams are now fully engaged and working to expedite the process of scaling to full production. In the near term, Canadian quality cannabis will be grown in Israel and available to Israeli customers. Canadian genetics, Israeli grown.”
On Behalf of The Board of Directors
pual
2 years ago
I wonder ... Did our new CEO canned our cannabis projects without mentionning it or has started a new business altogether ???
Isracann Adds Super Bowl MVP and Mental Health Advocate Mark Rypien to Advisory Board
08/23/2022 9:00:00 AM
VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) a multi-faceted organization with a natural health medicine division (Praesidio Health) in Canada and holdings in Israel, is please to announce the appointment of Super Bowl XXVI MVP and mental health advocate Mr. Mark Rypien to its advisory board.
CEO Phil Floucault notes, “Mr. Rypien had a distinguished 13-year career in the NFL during which he was named to the All Madden Team in 1992, twice named to the Pro Bowl (1988 and 1991) and the first and only Canadian born Super Bowl MVP. As is widely reported and, as a result of sustained trauma during that time, Mark has suffered and continues to deal with some long-term effects. It is his advocacy for other athletes, military and civilians that brought us together. We see a synergy of working together to provide access to mental health support and to improve the mental health of all people. Whether it be our military and civilians or our athletes both professional and amateur.”
Praesidio Health (https://www.praesidiohealth.com/) is a Canadian medical research company that develops and validates natural health products using an evidence-based process. Included in the first round of formulations submitted to Health Canada for review and approval is a product dubbed “Quiet Peace.” “The trauma that I sustained from my career definitely effected my mental health,” says Mark. “Back then, there were no concussion protocols. You just shook it off and kept playing. I have carried those tackles with me long after I retired. During a particularly low point in my mental wellbeing, I attempted suicide. That was a wake-up call for me. I had had enough of feeling this way. It was time to start talking about mental health.”
Since then, Mark has become an advocate for athletic mental health and the mental health of our military and civilians.
“I’m excited to work with the Praesidio team to bring awareness to mental health and the potential that Praesidio products bring as part of a treatment regimen. The issues that I have dealt with and am continuing to deal with are faced by many professional athletes, military, and civilians alike. I am looking forward to helping support them,” says Mark.
On Behalf of The Board of Directors
pual
2 years ago
I'm now stuck with 100,000 close to worthless value but I also think the company is trying to relaunch but I do not know in what context.
I honestly think management doesn't care about its shareholders and the value of their stock. Were they somewhat responsible people, they would (WITHOUT UNDUE MISLEADING PROMISSES) issue some kind of Corporate update describing honestly the current state of the company and the plans the management does try to realise.
As in many such stocks however, management has absolutely no respect to their shareholders and informing them APPROPRIATELY is not something they do care about.
I own only 2 OTC stocks and I intend to never buy another one, this market being made from irresponsible companies managements and worst even being manipulator by some, exploiting this crazy behavior at the cost of small hopeful investors.
OTC is a crappy unregulated market and playing roulette in a casino is offering as good a reward potential (negative or positive), faster.
I was not stupid enough to bet the rent money ... Thanks God.
GLTA, ... spin the wheel
pual
2 years ago
Isracann Biosciences Acquires Natural Health Medicine Developer and Appoints Natural Health Products Officers
04/13/2022 8:30:00 AM
VANCOUVER, British Columbia, April 13, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that, further to the Company’s news releases dated February 23, 2022 and March 28, 2022, it has closed its acquisition of Praesidio Health Inc. (“Praesidio”). Pursuant to the definitive agreement dated March 24, 2022 with Praesidio and the shareholders of Praesidio (the “Praesidio Shareholders”), the Company acquired all of the issued and outstanding shares in the capital of Praesidio (the “Praesidio Shares”) for aggregate consideration of C$4,000,000 in common shares (the “Consideration Shares”) in the capital of the Company (the “Transaction”). Praesidio will operate as a wholly-owned subsidiary of the Company.
Praesidio (https://www.praesidiohealth.com/) is an industry-leading, Canadian medical research company that develops and validates natural health products (“NHPs”) using an evidence-based process. Pioneering NHPs and therapeutics, Praesidio is actively developing several NHP candidates for utility in a range of conditions, including post-viral exposure prophylaxis, urological, anxiety/stress, immune boosting, and sleep aids. Praesidio employs formulation combinations with and without cannabinoids and/or psilocybin, which provides the opportunity for product development in conjunction with future operations in Israel, including direct access to European markets.
The Consideration Shares will be issued to the Praesidio Shareholders in seven tranches, with 12,210,008 Consideration Shares (the “First Instalment Shares”), having an aggregate deemed value of C$1,000,000, issued at closing of the Transaction (“Closing”) and Consideration Shares having an aggregate deemed value of C$500,000 being issued every six months thereafter until the third anniversary of the date of Closing. The price of the Consideration Shares will be equal to the volume weighted average of actual trading prices (measured in hundredths of cents) of the common shares in the capital of the Company on the Canadian Securities Exchange (the “CSE”) for the ten consecutive business days ending on the day that is two business days prior to the applicable date of issuance. The First Instalment Shares were issued at a deemed price of C$0.0819 per First Instalment Share. All Consideration Shares are subject to a contractual escrow period, with release dates ranging from 12 to 48 months following Closing.
The Company is also pleased to announce the appointments of Dr. George Vrabec and Bob Mehr to the positions of Director of Natural Health Products and Vice President of Natural Health Product Development, respectively, in connection with the Transaction. The appointments will take effect as of April 15, 2022.
Dr. George Vrabec, MD FRCSC (Urol.) is a Urologist and Surgeon with over 20 years of medical experience, as well as the Principal Investigator of Exdeo Clinical Research. Dr. Vrabec has conducted more than 30 clinical trials in a wide array of Urological diseases and has published studies in various journals, including the New England Journal of Medicine. Dr. Vrabec serves on multiple boards, including Fraser Valley Health Care Foundation.
Bob Mehr is the President and Chief Executive Officer of Pure Integrative Pharmacies, which operates 17 integrative pharmacies in British Columbia. Mr. Mehr has nearly 30 years of experience in the pharmacy services industry and has developed a number of formulations and supplements licensed by Health Canada. Mr. Mehr is a member of several professional associations, including the British Columbia College of Pharmacists and the British Columbia Pharmacy Association.
“We initially founded Praesidio with the goal of integrating NHPs into current medical practice. Our vision was to validate these treatments alongside conventional medical treatments, thereby empowering health providers and their patients in accessing such treatments. Today, we are very pleased to be partnering with the Isracann team, as we believe this will positively impact the development of our NHPs and the execution of our clinical strategy of ushering them into new medical standards of care,” states Dr. Vrabec.
Isracann CEO Phil Floucault notes, “We are very excited to have executed the first step in our natural health product strategic plan. It’s fantastic to actively build momentum towards revenue generation across North America and abroad. We are excited by the novel formulations, and we welcome aboard the entire Praesidio team who have brought some fantastic products, enthusiasm, and aggressive outlook to our venture. We look forward to working together to build a solid business opportunity and tangible shareholder value in the weeks and months ahead.”
The securities of the Company referred to in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws. Accordingly, the securities of the Company may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful.
pual
2 years ago
Isracann Biosciences Signs Definitive Agreement to Acquire Natural Health Medicine Developer - 03/28/2022 8:30:00 AM
VANCOUVER, British Columbia, March 28, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that, further to the Company’s news release dated February 23, 2022, it has entered into a definitive agreement (the “Agreement”) dated March 24, 2022 with Praesidio Health Inc. (“Praesidio”). Pursuant to the Agreement, the Company will acquire all of the issued and outstanding shares in the capital of Praesidio (the “Praesidio Shares”) for aggregate consideration of C$4,000,000 in common shares (the “Consideration Shares”) of the Company (the “Transaction”). Upon closing of the Transaction (“Closing”), Praesidio will operate as a wholly-owned subsidiary of the Company.
Praesidio Health (https://www.praesidiohealth.com/) is an industry-leading, Canadian medical research company that develops and validates natural health medicine (“NHM”) using an evidence-based process. Pioneering NHMs and therapeutics, Praesidio Health is actively developing several product candidates for utility in a range of conditions, including post-viral exposure prophylaxis, urological, anxiety/stress, immune booster, and sleep aids. The company employs formulation combinations with and without cannabinoids and/or psilocybin, which opens the opportunity for product development in conjunction with future operations in Israel including direct access to European markets.
The Consideration Shares will be issued in seven tranches, with C$1,000,000 of the Consideration Shares being issued at Closing and C$500,000 of the Consideration Shares being issued every six months thereafter until the third anniversary of the date of Closing. The price of the Consideration Shares will be equal to the volume weighted average of actual trading prices (measured in hundredths of cents) of the common shares in the capital of the Company on the Canadian Securities Exchange (the “CSE”) for the ten consecutive business days prior to the applicable date of issuance. The Consideration Shares will be subject to a 48-month contractual escrow period, which will begin on date of Closing.
The Transaction remains subject to certain closing conditions, including, without limitation, the receipt of all necessary corporate and regulatory approvals and other customary closing conditions. There can be no assurance that the Transaction will be completed as proposed or at all. Closing of the Transaction is expected to occur on or about April 4th, 2022.
The securities of the Company referred to in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws. Accordingly, the securities of the Company may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful.
pual
2 years ago
Certainly looks like it but, looking at the volume recently, a lot of people seem to be bying in. Would be nice however to know where from all these shares are coming from...
Over 1,000,000 shares traded within the last 4 trading days at a growing price (between 12 and 14 cents).
As of last Nov31, we seemed to have almost no debts and our number of O/S had been fixed at more or less 145,000,000 wit a market cap of more or less $20,000,000.
At that time, Morningstar established that the fair value of the stock was about $0,26 for a market cap of $37,000,000
Finally, our new CEO issued a NR 2 weeks ago (Isracann Signs LOI to Acquire Natural Health Medicine Developer) and, if we skip the NR's announcing nominations at the management top, this was a first after 11 months (April 21 - Isracann Receives Foreign Owners License and Updates Israeli Cannabis Operations)
I effectively am one of us 2 still believing that there may be a good future for this stock but I hope, the next year to be a lot more productive than the last one.
GLTY also.
pual
2 years ago
Isracann Signs LOI to Acquire Natural Health Medicine Developer
02/23/2022 8:30:00 AM
VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) a biosciences company focused on researching and developing innovative health solutions in conjunction with its advanced stage activities aimed at becoming a premier low-cost, high-quality cannabis producer/distributor is pleased to announce that it has entered into a binding LOI to acquire Praesidio Health Inc. of Canada (“Praesidio”).
The appointment of Mr. Phil Floucault to the position of Isracann’s Chief Executive Officer in late October of 2021, allowed for a period of investigation, reflection and ultimately offered an opportunity for Mr. Floucault to examine parallel complementary business opportunities within his extensive business network. With the COVID-19 global pandemic continuing to impact almost every business sector around the world, the continued governmental delays impeding the advancement of its cannabis operation in Israel, have led to a determination to advance a parallel opportunity which can be integrated and leveraged with the Israeli business operation in future.
Praesidio Health (https://www.praesidiohealth.com/) is an industry-leading, Canadian medical research company that develops and validates natural health medicine (NHM) using an evidence-based process. Pioneering NHMs and therapeutics, Praesidio Health is actively developing several product candidates for utility in a range of conditions, including post-viral exposure prophylaxis, urological, anxiety/stress, immune booster, and sleep aids. The company employs formulation combinations with and without cannabinoids and/or psilocybin which opens the opportunity for product development in conjunction with future operations in Israel including direct access to European markets.
Dr. George Vrabec MD FRCSC (Urol.), Chief Medical Officer at Praesidio Health notes, “We originally started as a group of physicians in 2018 with a common goal: to become a medical chaperone to patients requiring natural health-based medicines. Over the past decade, while the demand for natural health-based medicines has been rapidly increasing, we realized there was very limited clinical information available to our patients. Wanting to improve our patients' health and keep them safe, we formed Praesidio Health. By developing evidence-based clinical standards and guidelines focused on the use of NHMs, we help prescribing physicians optimize their patients’ treatment and safety across a wide range of medical diseases.”
Pioneering NHMs and therapeutics, Praesidio Health is actively developing several NHMs for utility in a range of urological conditions. The team is advancing evidence-based research on select NHMs showing clinical efficacy in proof-of-concept studies. Urological conditions affect approximately 40% of men over 50, and the aging male population in North America is driving sales of BPH drugs to projected revenues of 5 billion dollars (USD) by 2021.
Isracann’s CEO, Mr. Phil Floucault advises, “We are excited to have the opportunity to bring this world-class team onboard. Given the ongoing vagaries impacting our operations in Israel, I wanted to bring some momentum back to our project in a manner that offers real synergy and tangible mutual opportunity in future. I believe that Praesidio Health holds an extraordinary opportunity to unlock strategic value in the health sector and our acquisition agreement as a stock transaction based on $4M CAD reflects excellent value for our shareholders.”
The Company also announces it has signed an agreement with Promethean Marketing to provide digital marketing services. The terms are for the offering of services for one month beginning February 23, 2022. As consideration for the contract, the Company has made payments totaling US$65,000.
pual
2 years ago
I suggest that ISCNF (IPOT) has now become a great opportunity for large gains (pps a CDN$ 0,10 or US$ 0,08).
For almost all of 2021 the only news we got allowing to think that the company wasn’t dead were that, Isracann appointed a new Experienced Farm Manager (August) and a new CEO (October).
This week we find that: ‘Isracann has determined to return to a normalized business, focusing on:
- transition from development to operations at the Ein Hahoresh facility,
- differentiation, solid partnership strategies as well as immediate options to revenue,
- understanding how best to maximize operations in the near future and
- generating revenue and shareholder value in 2022.’
The new CEO said : ‘We don’t see any significant regulatory hurdles other than awaiting the final go-ahead from a government, believing the approvals are imminent’
The market cap of the company is still less than CDN $15m or US $12m and it looks (from more recent balance sheet) that debt is still relatively minimal(?).
By the way, according to MORNINGSTAR, fair value of the stock is already CDN $0,18 or US $0,145.
I plan to sit on my xxx,xxx shares, notwithstanding my high avg costs (CDN $0,195)
pual
2 years ago
Isracann Advises on Recent Activities and 2022 Outlook - 02/09/2022 8:30:00 AM
VANCOUVER, British Columbia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low-cost, high-quality cannabis producer/distributor is pleased to provide an update of recent activities and outlook for Q1 2022.
The COVID-19 global pandemic continues to impact virtually all aspects of supply chain management, global trade, individual economies, and of course holds the attention of national and regional governments as priorities are identified and addressed. It is against this constantly evolving backdrop that Isracann has determined to continue to achieve strategic momentum against the eventual return to a normalized business environment.
The appointment of Phil Floucault to the position of Chief Executive Officer in late October has provided a 2–3-month window of opportunity for perspective and understanding of virtually every aspect of the operational preparedness of the Company and its partners, consultants, and stakeholders.
Mr. Floucault commented, “The first 3 months of my appointment have been focused on our current path to transition from development to operations at our Ein Hahoresh facility. Additionally, we have taken the opportunity to consider our fundamental mission of becoming a true biosciences company as our name suggests.” This led Mr. Floucault to consider the company’s future potential and opportunities, building on his existing business relationships. “In parallel to our near-term priorities, we are also looking to the future with a focus on differentiation, solid partnership strategies as well as immediate options to revenue. There are opportunities we are actively exploring to complement our Israeli operation, which we hope will ensure a solid position for our company including a divested portfolio, multiple revenue stream options and a solid operational footprint throughout North America and abroad.”
As it relates to IPOT’s Israeli Operations Mr. Floucault states, “There is no good time to catapult into a business during a pandemic, but we play the cards we are dealt, and, in this instance, it has provided an opportunity for an end-to-end review of a venture on the precipice of commercialization without the added pressure of a learning curve during production. We’d all like to be growing, processing, and delivering product sales, but the current conditions have provided me the time to study and learn, build relations, and prepare for rapid advancement as soon as legally possible. We don’t see any significant regulatory hurdles other than awaiting the final go-ahead from a government that frankly has a lot on its plate right now,” continues Floucault. “I believe the approvals are imminent as we have been far more focussed on understanding how best to maximize operations in the near future.”
Mr. Floucault stated, “We are excited to have had the chance to update and build out our strategic plans, and the entire team is fully committed to generating revenue and shareholder value in 2022. We are all learning new ways to be patient, and we are grateful for the patience and trust exhibited by everyone who shares in the Isracann vision for success.” Floucault closed with, “Considering the last 2 years of development and the resulting delays due to the global pandemic, we have much work to do in 2022 domestically and abroad. Our commitment has never been higher and our focus, never better.”
ON BEHALF OF THE COMPANY
“Phil Floucault”
Phil Floucault,
Chief Executive Officer
pual
2 years ago
For whatever reason the market recently became somewhat more active around our stock. Since Dec. 30 (low PPS of $0,04) to today (PPS of $,085) volume did increase a lot.
Even if no one seems to read this board, I want to document herein why a press release outlining a corporate update is overdue. I wrote to our CEO requesting one.
Oct. 20, 2021-- Isracann Biosciences Inc. announces the appointment of Mr. Phil Floucault as CEO effective immediately.
Aug. 31, 2021 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. announces the appointment of Mr. Peleg Agayuf as Manager of Farm Operations and provides a corporate review and update of its activities in Israel. Recent activities at the Ein Hahoresh Farm include the following:
-The facility as proposed has been completed and are now fully constructed, with all related services and infrastructure installed.
-The requisite Ministry of Security and Ministry of Health inspections have been delayed but preliminary inspections were completed some time ago. Isracann has been advised that the requisite final inspections are anticipated within weeks.
-Once the inspections are concluded and approvals received, planting is allowed to commence immediately. The hiring of Mr. Peleg Agayuf brings timely oversight to start-up activities during and after the transition to operations.
-Regarding importation of products from Canada for Israel’s medical marketplace, recent Israeli regulatory rule changes impacted all cannabis importers negatively. Isracann and its local partners have utilized the time to carefully finalize a supply chain pathway. Applications are underway to secure importation rights.
-The Company’s Nir, Yisreal farm is complex due to regional issues specific to public lands. Company consultants are currently updating plans to align and comply with Settlement Commission requests.
-Isracann COO Matt Chatterton notes, “The good news is that our construction team at Ein Hahoresh continued their efforts and concluded their work at the farm and as part of our transition to commercialization we have utilized our time by increasing our processing capacity in order that we might more rapidly catch up and possibly surpass our original production expectations.
Whenever significant change can or does impact our investment, the company must update the market. Hard to believe that nothing 'significant' (except nominating a CEO) did happen within the last 5 months.
A corporate updated is now required and overdue.
pual
3 years ago
After I sold my 150,000 shares at an avg price of $0,199, considering the company finally did show a minimum sign of life issuing a PR (Isracann Appoints Experienced Farm Manager and Updates Israeli Cannabis Operations 08/31/2021) I decide to gradually buyback in (35,000 shares) at $0,105.
I will not hold my breath but wouldn't it be nice if management had the honesty and decency to issue a corporate update of eher they come from, where they stand and what their plans are (objectives, obstacle, solutions, actions).
An honest check point news is not now just suitable, it is require if management has some respect for its remaining shareholders.
News
Market Data
Register for real-time alerts, custom portfolio, and market movers
